Pluristem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on September 11, 2014. The company, incorporated in Nevada with principal offices in Haifa, Israel, is reporting the termination of a material definitive agreement.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the termination of a capital raising agreement.
Material Changes
On September 11, 2014, Pluristem notified MLV & Co. LLC of the termination of their At Market Issuance Sales Agreement, originally entered into on December 26, 2012. Under this agreement, the company could have issued and sold up to $95,000,000 of common stock. The termination is effective September 21, 2014. The company stated it does not intend to utilize the agreement to raise additional capital. No termination penalties were incurred.
Guidance, Outlook, and Risks
Management commentary indicates a strategic decision to cease using this specific sales agreement for capital raising. The filing does not contain forward-looking guidance, updated risk factors, or details on contingencies beyond the termination event.
Key Facts for Investor Verification
- Termination of the $95 million At Market Issuance Sales Agreement with MLV & Co. LLC.
- Effective date of termination is September 21, 2014.
- No financial penalties were incurred for the termination.
- The company explicitly stated it does not intend to use this agreement for future capital raises.
- Review the original Sales Agreement filed as Exhibit 1.1 to the December 26, 2012 Form 8-K for full terms.